SGLT2 Inhibitors in Diabetic Kidney Disease
Sophia Zoungas, Ian H. de Boer
Abstract
Type 2 diabetes, increasing in prevalence globally, is a major cause of CKD and kidney failure. Sodium-glucose transport protein 2 inhibitors (SGLT2i) significantly reduced progression of CKD, major adverse cardiovascular events, heart failure, and all-cause mortality in large clinical trials of
Topics & Concepts
MedicineKidney diseaseAdverse effectInternal medicineDiabetes mellitusDiseaseClinical trialKidneyType 2 diabetesHeart failureEndocrinologyRenal functionGastroenterologyMEDLINECardiologyCause of deathDiabetic nephropathyPharmacologyUrologyHeart diseaseAlbuminuriaDiabetes Treatment and ManagementPancreatic function and diabetesPharmacology and Obesity Treatment